Additionally, this combination modifies the immune microenvironment, as PARP inhibitors increase tumor immunogenicity, while antiangiogenic agents counteract VEGF-driven immunosuppression, boosting anti-tumor immunity [12]. Here, VEGFA is linked to neoplasm.